Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Review: Eosinophilic Esophagitis.

6 Oct, 2021 | 09:51h | UTC

Eosinophilic Esophagitis: A Review – JAMA (free for a limited period)

Related:

Randomized trial: Budesonide orodispersible tablets maintain remission in patients with eosinophilic esophagitis

Clinical Guidelines for the Management of Eosinophilic Esophagitis

Eosinophilic Esophagitis: Review and Update

 


Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

3 Oct, 2021 | 22:49h | UTC

Covid-19 vaccination: evidence of waning immunity is overstated – The BMJ

Related:

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 


Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

24 Sep, 2021 | 08:55h | UTC

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events – Journal for ImunoTherapy of Cancer

Related:

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment (several resources on the subject)

 


Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

23 Sep, 2021 | 10:16h | UTC

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial – The Lancet Infectious Diseases

Related: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

 


Systematic review: Clinical characteristics of multisystem inflammatory syndrome in adults.

23 Sep, 2021 | 10:12h | UTC

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review – JAMA Network Open

 

Commentary on Twitter

 


An FDA panel says only high-risk Americans and those 65+ should get covid boosters.

19 Sep, 2021 | 23:45h | UTC

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR

See also:

FDA advisory panel recommends booster doses of Covid-19 vaccine only for older and high-risk Americans – STAT

5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN

Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press

Related:

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

Third shot: UK to offer COVID booster jabs to over 50s.

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

COVID vaccine effects wane over time but still prevent death and severe illness.

What’s the evidence for COVID-19 booster shots?

WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

 


COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

19 Sep, 2021 | 23:40h | UTC

COVID vaccine immunity is waning — how much does that matter? – Nature

 


Case series: Vaccine-induced thrombocytopenia with severe headache may precede cerebral venous sinus thrombosis by several days – patients with severe headache 5 to 20 days after adenovirus vector vaccination against Covid-19 should undergo immediate testing for thrombocytopenia and d-dimer levels and, if available, testing for anti–PF4–heparin IgG antibodies.

16 Sep, 2021 | 10:14h | UTC

Vaccine-Induced Thrombocytopenia with Severe Headache – New England Journal of Medicine

 

Commentary on Twitter

 


COVID vaccine effects wane over time but still prevent death and severe illness.

16 Sep, 2021 | 10:10h | UTC

COVID vaccine effects wane over time but still prevent death and severe illness – The Conversation

Related:

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 


An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

16 Sep, 2021 | 10:13h | UTC

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel – New England Journal of Medicine

 


COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

14 Sep, 2021 | 10:08h | UTC

News release: COVID-19 vaccine efficacy does not support boosters for general population, review concludes – The Lancet

Original article: Considerations in boosting COVID-19 vaccine immune responses – The Lancet

Commentaries:

FDA experts among group opposing US booster shot plan – Associated Press

FDA vaccine regulators argue against Covid-19 vaccine boosters in new international review – STAT

Global experts pan wider use of COVID vaccine booster dose – CIDRAP

Expert reaction to viewpoint article on COVID-19 booster vaccines for general populations – Science Media Centre

Boosters Are ‘Not Appropriate’ – Reach Unvaccinated First – Health Policy Watch

Data Doesn’t Support Need for COVID-19 Vaccine Boosters: Experts – HealthDay

In a new review, some F.D.A. scientists and others say boosters aren’t needed for the general population. – The New York Times

 


What’s the evidence for COVID-19 booster shots?

12 Sep, 2021 | 22:05h | UTC

What’s the evidence for COVID-19 booster shots? – Canadian Medical Association Journal

 


COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it.

10 Sep, 2021 | 05:29h | UTC

COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it – The Conversation

Original study and commentary: [Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.

 


India’s DNA COVID vaccine is a world first – more are coming.

10 Sep, 2021 | 05:30h | UTC

India’s DNA COVID vaccine is a world first – more are coming – Nature

 


Perspective | What we actually know about waning immunity.

10 Sep, 2021 | 05:26h | UTC

What We Actually Know About Waning Immunity – The Atlantic

 


[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.

9 Sep, 2021 | 09:55h | UTC

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial – medRxiv

 

Commentary on Twitter (thread – click for more)

https://twitter.com/hildabast/status/1435720202147143680

 


Kids and COVID: why young immune systems are still on top.

7 Sep, 2021 | 21:46h | UTC

Kids and COVID: why young immune systems are still on top – Nature

 


[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

7 Sep, 2021 | 21:42h | UTC

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals – medRxiv

 

Commentary on Twitter

 


Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.

7 Sep, 2021 | 10:56h | UTC

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) – The Lancet

Invited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine

 

Commentaries on Twitter

(thread – click for more)

(thread – click for more)

 


Opinion | Video: Immunity is the only way through a pandemic (w/Dr. Monica Gandhi).

7 Sep, 2021 | 10:45h | UTC

Immunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD

 


EU agency says to focus on vaccines first not booster shots.

3 Sep, 2021 | 10:34h | UTC

EU agency says to focus on vaccines first not booster shots – Associated Press

See also: European officials say COVID-19 booster isn’t urgent – CIDRAP

 


RCT: In patients with Immune Thrombocytopenia, the addition of Mycophenolate Mofetil to a standard glucocorticoid regimen reduced refractory or relapsed disease but was associated with decreased quality of life outcomes regarding physical function and fatigue.

3 Sep, 2021 | 10:15h | UTC

Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia – New England Journal of Medicine

 


Review | COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.

2 Sep, 2021 | 10:06h | UTC

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses – The Lancet Rheumatology

 

Commentary on Twitter

 


Another study shows Pfizer mRNA vaccine immunity is reduced over time.

2 Sep, 2021 | 10:05h | UTC

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar – medRxiv

Related:

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 

Commentary on Twitter (thread – click for more)

 


[Preprint] Pfizer vaccine booster dose protection: A nationwide study from Israel – “Twelve days or more after the booster dose we found an 11.4-fold decrease in the relative risk of confirmed infection, and a >10-fold decrease in the relative risk of severe illness”.

1 Sep, 2021 | 09:59h | UTC

BNT162b2 vaccine booster dose protection: A nationwide study from Israel – medRxiv

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.